Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
03 Octubre 2023 - 6:00AM
Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral
presentation and four posters highlighting its development program
for Pompe disease will be included at the 28th Annual Congress of
the World Muscle Society (WMS), being held October 3-7, 2023 in
Charleston, SC.
Oral Presentation:
Abstract Title: 104-week
efficacy and safety of cipaglucosidase alfa + miglustat in patients
with late-onset Pompe disease previously treated with alglucosidase
alfa (Oral #O21)
- Presenter: Tahseen
Mozaffar, MD, Department of Neurology, University of California,
Irvine, CA, U.S.A.
- Date and time:
Saturday, October 7, 7:45-8:45 a.m. E.T.
- Location: PAC,
Charleston Area Convention Center
Poster Sessions:
Abstract Title: Switching
treatment to cipaglucosidase alfa plus miglustat positively affects
motor function and quality of life in patients with late-onset
Pompe disease (Poster #P371)
- Presenter: Kristl
G. Claeys, MD, PhD, University Hospitals Leuven, Leuven,
Belgium
- Poster Session 3:
Friday, October 6, 2:00-3:00 p.m. E.T.
- Location: Ballroom
A-C, Charleston Area Convention Center
Abstract Title: Effect size
analysis of cipaglucosidase alfa plus miglustat versus
alglucosidase alfa in ERT-experienced adults with late-onset Pompe
disease in PROPEL (Poster #P373)
- Presenter: Jordi
Díaz-Manera, MD, PhD, John Walton Muscular Dystrophy Research
Centre, Newcastle upon Tyne, U.K.
- Poster Session 3:
Friday, October 6, 2:00-3:00 p.m. E.T.
- Location: Ballroom
A-C, Charleston Area Convention Center
Abstract Title: Safety of home
administration of cipaglucosidase alfa plus miglustat in late-onset
Pompe disease: results from multiple clinical trials (Poster
#P372)
- Presenter: Barry
J. Byrne, MD, PhD, University of Florida, Gainesville, FL,
U.S.A.
- Poster Session 3:
Friday, October 6, 2:00-3:00 p.m. E.T.
- Location: Ballroom
A-C, Charleston Area Convention Center
Abstract Title: Disease burden,
treatment patterns and healthcare resource utilization associated
with Pompe disease in Sweden: a real-world evidence study (ePoster
#VP369)
- Presenter:
Christopher Lindberg, MD, Neuromuscular Centre, Sahlgrenska
University Hospital, Gothenburg, Sweden
- Poster Session 3:
Friday, October 6, 2:00-3:00 p.m. E.T.
- Location: Virtual
Platform
For more information on the World Muscle Society
2023, please visit wms2023.com.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated
biotechnology company focused on discovering, developing and
delivering novel high-quality medicines for people living with rare
diseases. With extraordinary patient focus, Amicus Therapeutics is
committed to advancing and expanding a pipeline of cutting-edge,
first- or best-in-class medicines for rare diseases. For more
information please visit the company’s website at www.amicusrx.com,
and follow on Twitter and LinkedIn.
CONTACTS:
Investors: Amicus Therapeutics Andrew
FaughnanVice President, Investor
Relationsafaughnan@amicusrx.com(609) 662-3809
Media: Amicus Therapeutics Diana Moore Head of
Global Corporate Communicationsdmoore@amicusrx.com(609)
662-5079
FOLD–G
Amicus Therapeutics (NASDAQ:FOLD)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Amicus Therapeutics (NASDAQ:FOLD)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024